De novo malignancy after kidney transplantation

Abstract

Kidney transplantation is improving quality of life as well as life expectancy. However, immunosuppressive drugs after kidney transplantation are increasing the standardized incidence ratio and cumulative incidence of malignant tumors. Malignancies have also recently become the leading cause of death among kidney transplant recipients. In recent years, the frequency of malignancy is increasing due to the long-term viability and survival of kidney transplant recipients and the increasing potency of immunosuppressive drugs. Malignancy control is needed to further improve the outcome of kidney transplantation. In this article, we would like to clarify the characteristics, screenings and managements of de novo malignancy after kidney transplantation.